Target intelligence / Profile preview

D-alanyl-D-alanine terminus of nascent peptidoglycan

Molecular classification
Other (peptidoglycan terminus, non-protein molecular motif)
01

Overview

The **D-alanyl-D-alanine terminus of nascent peptidoglycan** is a short peptide motif found at the end of the stem peptide in newly synthesized bacterial peptidoglycan precursors. This motif is critical for **bacterial cell wall synthesis**, as it serves as the recognition site for transpeptidase enzymes that cross-link the peptidoglycan strands, giving the cell wall its mechanical strength and protecting bacteria from osmotic lysis[1][4][7]. Some antibiotics, most notably vancomycin, target this terminus by binding directly and blocking cross-linking, leading to inhibition of cell wall synthesis and bacterial death. Alterations of this terminus, such as D-Ala-D-Lac substitution, confer clinically relevant antibiotic resistance[10]. This motif is therefore a major **therapeutic target** in the treatment of bacterial infections and is implicated in the mechanism of action of several critical antibiotic classes.

Other names
D-Ala-D-AlaD-alanyl-D-alanineD-Ala-D-Ala motifD-alanyl-D-alanine moietyterminal D-Ala-D-Ala
02

Mechanism of action

Vancomycin and related antibiotics bind directly to the D-Ala-D-Ala terminus, preventing transpeptidase-mediated cross-linking of peptidoglycan and thereby inhibiting cell wall synthesis[10][1]. β-lactam antibiotics mimic the D-Ala-D-Ala structure, irreversibly inactivating transpeptidases that catalyze cross-linking, though they do not directly bind the terminus—rather, they compete at the enzyme’s active site[1].

03

Biological functions

Bacterial cell wall biosynthesisMaintenance of cell wall integritySubstrate recognition site for transpeptidases and some antibiotics
04

Disease associations

Infection (due to its essential role in bacterial survival and as a key determinant of antibiotic action against bacteria)
05

Safety considerations

Antibiotic resistance development, such as replacement of D-Ala-D-Ala with D-Ala-D-Lac, leading to loss of antibiotic binding (not a direct safety concern, but a therapeutic challenge)[10]
06

Interacting drugs

Vancomycin

3 more in the full profile.

07

Biomarkers

There are no established clinical biomarkers based on the D-Ala-D-Ala terminus, though resistance can be inferred if target modification, such as D-Ala-D-Lac replacement in vancomycin-resistant bacteria, is detected

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of nascent peptidoglycan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of nascent peptidoglycan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call